| scholarly article | Q13442814 |
| P50 | author | Paul A. Rota | Q88475153 |
| Azaibi Tamin | Q88585554 | ||
| P2093 | author name string | Matthias Liniger | |
| Hussein Y Naim | |||
| David Kelvin | |||
| Marian Wiegand | |||
| Armando Zuniga | |||
| Marlyse Knuchel | |||
| Rene R Marty | |||
| Sara Weibel | |||
| Teldja N Azzouz-Morin | |||
| P2860 | cites work | Chimeric measles viruses with a foreign envelope | Q27469529 |
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. | Q32157164 | ||
| Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice | Q33696283 | ||
| Measles virus spread and pathogenesis in genetically modified mice | Q33783885 | ||
| Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. | Q33834543 | ||
| A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies | Q34338054 | ||
| Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications | Q34460359 | ||
| A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. | Q34552313 | ||
| Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. | Q34996026 | ||
| SARS coronavirus: a new challenge for prevention and therapy | Q35143451 | ||
| Dendritic cells and measles virus infection. | Q35149894 | ||
| Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life | Q35172905 | ||
| Measles virus and immunomodulation: molecular bases and perspectives | Q35571096 | ||
| The aetiology, origins, and diagnosis of severe acute respiratory syndrome. | Q35937519 | ||
| The SARS-CoV S glycoprotein | Q35938995 | ||
| Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector | Q36202976 | ||
| Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity | Q36449078 | ||
| Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association | Q36602721 | ||
| The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. | Q36651219 | ||
| Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren | Q36937679 | ||
| Attenuated measles virus as a vaccine vector | Q36999524 | ||
| Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus | Q37423250 | ||
| Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets | Q37596935 | ||
| A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. | Q39594077 | ||
| Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization | Q40108339 | ||
| A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice | Q40312310 | ||
| Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis | Q40518762 | ||
| A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice | Q40520942 | ||
| A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination | Q40778595 | ||
| Rescue of measles viruses from cloned DNA. | Q40790034 | ||
| Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway | Q40830206 | ||
| Reverse Genetics Meets the Nonsegmented Negative-Strand RNA Viruses | Q43719139 | ||
| A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. | Q44110039 | ||
| Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice | Q44961556 | ||
| A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children | Q45035494 | ||
| Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. | Q45622393 | ||
| Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins | Q45746948 | ||
| A recombinant measles virus expressing biologically active human interleukin-12. | Q45751457 | ||
| Role of virus strain dm conventional and enhanced measles plaque neutralization test | Q45791537 | ||
| Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus | Q45798836 | ||
| Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial | Q46797251 | ||
| Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates | Q46957936 | ||
| Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys | Q47812425 | ||
| Medicine. Caution urged on SARS vaccines | Q48019790 | ||
| Effects of a SARS-associated coronavirus vaccine in monkeys. | Q51639488 | ||
| Severe acute respiratory syndrome | Q56775278 | ||
| Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses | Q73636588 | ||
| Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months | Q74442119 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| measles | Q79793 | ||
| SARSr-CoV | Q278567 | ||
| Coronaviridae | Q1134583 | ||
| SARS-CoV-1 | Q85438966 | ||
| P304 | page(s) | 2164-2174 | |
| P577 | publication date | 2008-02-22 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses | |
| P478 | volume | 26 |
| Q30378994 | A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. |
| Q40245153 | A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus |
| Q39615678 | AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats |
| Q35887095 | An immune competent mouse model for the characterization of recombinant measles vaccines |
| Q26700080 | Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination |
| Q51932689 | Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. |
| Q36363203 | Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster |
| Q92076061 | Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |
| Q40259612 | Development of Recombinant Measles Virus-Based Vaccines |
| Q41610797 | Development of a duplex real-time RT-qPCR assay to monitor genome replication, gene expression and gene insert stability during in vivo replication of a prototype live attenuated canine distemper virus vector encoding SIV gag. |
| Q41557807 | Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. |
| Q39726079 | Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse |
| Q44581629 | Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic |
| Q89878795 | Measles Vaccines Designed for Enhanced CD8+ T Cell Activation |
| Q41612319 | Measles virus |
| Q50151207 | Measles-derived vaccines to prevent emerging viral diseases |
| Q37143501 | Middle East respiratory syndrome vaccines |
| Q38202354 | Morbillivirus vaccines: recent successes and future hopes |
| Q38830323 | Multivalent and Multipathogen Viral Vector Vaccines |
| Q37373733 | Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine |
| Q36183321 | Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates |
| Q30359923 | Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. |
| Q96110952 | Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis |
| Q38675786 | Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein |
| Q57989514 | Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus |
| Q38631790 | Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens |
| Q36366466 | Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma |
| Q45386726 | Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses |
| Q37366744 | Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity |
| Q37943585 | Recombinant vaccines against the mononegaviruses--what we have learned from animal disease controls |
| Q41871491 | Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector |
| Q37386899 | Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. |
| Q37524036 | SARS vaccines: where are we? |
| Q37478331 | Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector |
| Q48325941 | Type I interferon signaling protects mice from lethal henipavirus infection. |
| Q38657271 | Vaccine platform recombinant measles virus |
| Q38778044 | Vaccines for the prevention against the threat of MERS-CoV. |
Search more.